Orchid Pharma
- Market cap
- ₹ 4,153 Cr.
- P/E
- 287.2x
- P/B
- 3.35x
- 52-week range
- 480 – 1,143.5
- ROE
- 1%
- ROCE
- 2%
- Dividend yield
- 0%
- Debt / equity
- 0.2
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Orchid Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)287.2 against a typical 34.3: pricier than most peers (1st = cheapest).208th of 220
- Sales growth+15.6% against a typical +15.6% from a year earlier.99th of 197
- Share price, 3 months−14% against a typical −0.5%.161st of 200
- Size₹ 4,153.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).58th of 199
Latest announcements
Exchange filings and their impact on the company.
- Orchid won a 9-country LatAm licensing and supply deal for Exblifep worth ~USD 80m over 10 years, with minimal revenue in the next 12 months pending approvals.
Orchid Pharma signed an exclusive licensing and supply agreement with Laboratorio Libra for its antibiotic Exblifep (cefepime/enmetazobactam) in nine Latin American markets including Chile, Panama and Uruguay. Orchid will manufacture and supply the finished product while Libra will register, import and market it, subject to local approvals. The companies see a potential commercial opportunity of about USD 80 million over the first 10 years.
- Board approved enabling resolution to raise up to Rs 600 crore via equity or convertible modes.
Orchid Pharma's board on October 20, 2026 approved an enabling resolution to raise up to Rs 600 crore. The funds could be raised via equity shares, convertible debentures, QIP, preferential issue, public issue or other modes, subject to shareholder and regulatory approvals. No price, structure or timetable was disclosed; it is an enabling approval to explore market opportunities.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB+ by CARE- CARE lowered its rating on 8 Apr 2026.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB+ | Stable | 8 Apr 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Apr 2026 | ▼ Downgrade1 notch | CARE A- (Rating Watch with Developing Implications) → CARE BBB+ | — | CARE | ₹ 366.5 Cr. | |
| 7 Aug 2025 | Reaffirmed | CARE A- (Rating Watch with Developing Implications) | — | CARE | ₹ 366.5 Cr. |
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 20 Oct 2026 | Other | Board approved | ₹ 600 Cr. | — | — |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 20 Oct 2026 | Fund Raising | To consider and approve enabling resolution for Raising of funds |
| 14 Aug 2026 | Financial Results | To consider and approve the unaudited limited reviewed financial results (standalone and consolidated) for the period ended June 30, 2026 and restated audited standalone and consolidated financial results for Quarter and Financial year ended March 31, 2026 on account of Scheme of Amalgamation coming into effect. |
| 1 Aug 2026 | Other business matters | Prior intimation of Board Meeting scheduled to be held on August 01, 2026 |
| 25 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 11 Feb 2026 | Financial Results | To consider consider and approve Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-III of Financial Year 2025-26 ended on December 31, 2025. |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 199 | 221 | 217 | 244 | 223 | 217 | 237 | 263 | 194 | 207 | 368 | 304 |
| Expenses | 175 | 185 | 188 | 212 | 192 | 191 | 209 | 269 | 195 | 206 | 338 | 290 |
| Operating Profit | 23 | 35 | 29 | 32 | 30 | 26 | 28 | −6 | −1 | 2 | 30 | 14 |
| OPM % | 11.7% | 16% | 13.3% | 13.3% | 13.6% | 12.1% | 11.8% | −2.2% | −0.8% | 0.8% | 8.2% | 4.6% |
| Other Income | 8 | 8 | 13 | 8 | 8 | 8 | 4 | 12 | 11 | −2 | 8 | 2 |
| Interest | 4 | 4 | 3 | 4 | 3 | 4 | 4 | 2 | 4 | 3 | 2 | 2 |
| Depreciation | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 11 | 9 | 9 | 11 | 11 |
| Profit before tax | 20 | 30 | 30 | 28 | 26 | 22 | 19 | −7 | −3 | −12 | 25 | 3 |
| Tax % | 0% | 0% | −10.3% | −0.5% | 0% | 0% | −0.2% | 0% | 0% | 0% | 0% | 2.6% |
| Net Profit | 20 | 29 | 33 | 29 | 27 | 21 | 22 | −6 | −6 | −13 | 26 | 3 |
| EPS in Rs | 3.9 | 5.8 | 6.5 | 5.79 | 5.37 | 4.1 | 4.39 | −1.12 | −1.13 | −2.49 | 5.09 | 0.63 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 4%
- 5 Years
- 22%
- 3 Years
- 23%
- TTM
- 14%
- 10 Years
- 8%
- 5 Years
- 17%
- 3 Years
- 40%
- TTM
- −72%
- 10 Years
- 39%
- 5 Years
- 21%
- 3 Years
- 20%
- TTM
- —
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Orchid Pharma | ₹ 861.10 | ₹ 4,153 Cr. | 287.2x | 3.4x | 1% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sunil Kumar Gupta
- Chief Financial Officer
- Kapil Dayya
- Compliance Officer, Company Secretary
- R. J. Sarangdhar
- Vice President, Unit Head - API and FDF
- Manish Dhanuka
- Managing Director, Executive Director
- Mridul Dhanuka
- Whole Time Director
- Srinivasan S
- Head - CTD and IPM
Prices are delayed and for information only. Nothing on this page is investment advice.